LNSR LENSAR, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1320350 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.3%
TTM net income YoY-292.7%
TTM EPS YoY-289.8%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—
Margins
Gross margin47.2%
Operating margin-25.0%
Net margin-84.5%
FCF margin-9.0%
EBITDA margin-19.3%
Returns
ROE-16,631.7%
ROA-74.8%
ROIC (approx.)—
Asset turnover0.89x
Leverage & solvency
Liabilities / assets113.2%
Debt / equity—
Current ratio1.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-67.0%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.13M | $16.50M | $13.43M | $16.02M | $14.32M | $13.94M | $14.16M | $16.73M |
| Cost of revenue | $5.97M | $6.72M | $7.05M | $9.09M | $8.28M | $6.91M | $7.03M | $9.62M |
| Gross profit | $8.16M | $9.78M | $6.38M | $6.94M | $6.04M | $7.02M | $7.12M | $7.11M |
| R&D expense | $1.31M | $1.27M | $1.39M | $1.30M | $1.37M | $1.43M | $1.53M | $1.33M |
| SG&A expense | $8.06M | $6.14M | $2.53M | $10.33M | $12.02M | $11.66M | $11.15M | $6.83M |
| Operating income | -$1.43M | $2.13M | $2.24M | -$4.92M | -$7.58M | -$6.29M | -$5.79M | -$1.29M |
| Income tax | $0 | $0 | $0 | — | $0 | $0 | $0 | — |
| Net income | -$4.72M | $3.54M | $36.33M | -$1.46M | -$3.71M | -$1.76M | -$27.34M | -$18.70M |
| EBITDA | -$590,000 | $3.01M | $3.14M | -$3.98M | -$6.65M | -$5.42M | -$4.95M | -$416,000 |
| EPS (basic) | -0.38 | 0.14 | 1.56 | — | -0.31 | -0.15 | -2.32 | — |
| EPS (diluted) | -0.38 | 0.10 | 0.00 | — | -0.31 | -0.15 | -2.32 | — |
| Weighted avg. shares (diluted) | 12.40M | 23.03M | 15.42M | — | 12.04M | 11.94M | 11.77M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $12.62M | $13.56M | $12.49M | $12.97M | $7.64M | $7.15M | $19.55M | $16.26M |
| Short-term investments | $0 | $0 | $1.00M | $5.00M | $9.23M | $13.16M | $5.70M | $6.19M |
| Receivables | $5.14M | $6.17M | $4.90M | $6.38M | $5.90M | $4.99M | $6.88M | $6.08M |
| Inventory | $25.14M | $24.87M | $23.10M | $21.52M | $20.60M | $19.24M | $15.32M | $11.43M |
| Current assets | $44.49M | $47.03M | $42.40M | $46.77M | $44.43M | $45.87M | $49.19M | $41.98M |
| PP&E, net | $524,000 | $445,000 | $457,000 | $505,000 | $555,000 | $609,000 | $577,000 | $664,000 |
| Intangibles | $4.51M | $4.73M | $4.96M | $5.19M | $5.42M | $5.65M | $5.88M | $6.11M |
| Total assets | $67.07M | $69.56M | $66.22M | $71.43M | $70.20M | $70.41M | $72.96M | $66.30M |
| Current liabilities | $19.81M | $19.64M | $17.80M | $40.57M | $35.73M | $30.09M | $27.17M | $15.00M |
| Total liabilities | $42.22M | $40.87M | $41.65M | $83.67M | $82.33M | $79.68M | $81.32M | $47.65M |
| Shareholders' equity | $11.07M | $14.90M | $10.79M | -$26.02M | -$25.91M | -$23.05M | -$22.14M | $4.86M |
| Shares outstanding | 12.29M | 12.28M | 12.10M | 11.99M | 11.94M | 11.93M | 11.79M | 11.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$866,000 | -$127,000 | -$4.27M | $618,000 | -$3.51M | -$5.00M | -$6.94M | $3.66M |
| Capital expenditure | $112,000 | — | — | $0 | $0 | $77,000 | $6,000 | $3,000 |
| Free cash flow | -$978,000 | — | — | $618,000 | -$3.51M | -$5.08M | -$6.94M | $3.65M |
| Investing cash flow | -$112,000 | $965,000 | $4.00M | $4.25M | $4.00M | -$7.49M | $531,000 | $1.99M |
| Financing cash flow | $35,000 | $233,000 | -$209,000 | $474,000 | $0 | $93,000 | $9.69M | $172,000 |
| Depreciation & amortization | $843,000 | $878,000 | $904,000 | $944,000 | $928,000 | $865,000 | $844,000 | $874,000 |
| Stock-based compensation | $850,000 | $347,000 | $690,000 | $873,000 | $850,000 | $766,000 | $654,000 | $662,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.